Argenx SE Surges to 484th in Trading Volume with VYVGART Approval

On June 20, 2025, argenx SE (ARGX) saw a significant surge in trading volume, with a total of 1.82 billion shares exchanged, marking a 33.26% increase from the previous day. This surge placed argenx in the 484th position in terms of trading volume for the day, highlighting a notable increase in investor interest. The stock price of argenx rose by 0.88%.

On June 20, 2025, argenx SE announced that the European Commission has approved VYVGART® (efgartigimod alfa) 1000mg for subcutaneous injection as a monotherapy for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval is significant as it marks the first novel mechanism of action for CIDP treatment in over 30 years, based on the results of the ADHERE clinical trial, the largest study of CIDP patients to date.

VYVGART® SC is the first and only IgG Fc-antibody fragment targeting the neonatal Fc receptor (FcRn) approved for CIDP in Europe. The ADHERE trial showed significant clinical improvement in 66.5% of patients treated with VYVGART SC. This approval provides a new treatment option for CIDP, a debilitating autoimmune disorder, offering hope to patients and healthcare providers. VYVGART SC offers a convenient self-injection option, enhancing patient accessibility and compliance.

Despite the approval, 85% of CIDP patients still require ongoing treatment, and 88% experience residual impairment. The long-term effects and broader applicability of VYVGART SC in diverse patient populations remain to be fully understood. From a financial standpoint, the approval of VYVGART SC in Europe represents a significant milestone for argenx SE, potentially boosting its market share in the autoimmune disease treatment sector. The novel mechanism of action and the convenience of self-administration could drive strong adoption rates, translating into increased revenue streams. However, investors should remain cautious of the competitive landscape and the inherent risks associated with drug development and market acceptance.

The approval of VYVGART SC positions argenx SE as a leader in the CIDP treatment market, addressing a significant unmet medical need. The European market, with its 27 member states, along with Iceland, Liechtenstein, and Norway, offers a substantial opportunity for market penetration. The success of VYVGART SC could pave the way for further approvals in other regions, expanding argenx's global footprint. Continuous monitoring of patient outcomes and market feedback will be crucial in maintaining competitive advantage.